Received Jun 25, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| COVID19 | COVID19 (COVID19 (PFIZER-BIONTECH)) | PFIZER\BIONTECH | 1 | — | — |
It was confusion and then like extreme like fatigue to the point where the patient like, they ended up not attending an important meeting that they had; It was confusion and then like extreme like fatigue to the point where the patient like, they ended up not attending an important meeting that they had; This is a spontaneous report received from a Nurse. A 70-year-old female patient received BNT162b2 omicron (kp.2) (COMIRNATY (2024-2025 FORMULA)), as dose 1, single (Batch/Lot number: unknown) for covid-19 immunisation. The patient's relevant medical history included: "Hyperlipidemia" (ongoing). Concomitant medication(s) included: ROSUVASTATIN taken for hyperlipidaemia. The following information was reported: CONFUSIONAL STATE (non-serious), FATIGUE (non-serious) all with onset 2025, outcome "unknown" and all described as "It was confusion and then like extreme like fatigue to the point where the patient like, they ended up not attending an important meeting that they had". Additional information: The patient is reaching out from a doctor's office, internal medicine. We do have patient that recently completed one of the Pfizer like the vaccines for COVID (Later clarified as Pfizer COVID-19 vaccine) and so, the next day, the patient had some side effects that doctor wanted to report. So, it was confusion and then like extreme like fatigue to the point where the patient like, they ended up not attending an important meeting that they had. Reporter stated, it has been about a month since the start date of side effects. The information on the batch/lot number for BNT162b2 omicron (kp.2) will be requested and submitted if and when received.
Hyperlipidemia
ROSUVASTATIN